Synergy Empire LTD 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Synergy Empire Limited reports Q3 2025 results, detailing a strategic pivot to biopharmaceutical contract manufacturing following the acquisition of Meluha Therapeutics Berhad.
Synergy Empire Limited reports Q2 2025 results, detailing a strategic pivot to biopharmaceutical contract manufacturing following a reverse takeover.
Synergy Empire Limited reports Q1 2025 revenue of $12,500, a significant increase from zero in the prior year, driven by its new consultancy services business.
Synergy Empire Limited's Q3 2024 results show a significant revenue decrease due to the termination of tenancy agreements, offset by new lease revenue.